echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Heavy! Johnson and Johnson's $6.5 billion acquisition of Momenta strengthens autoimmune disease pipelines.

    Heavy! Johnson and Johnson's $6.5 billion acquisition of Momenta strengthens autoimmune disease pipelines.

    • Last Update: 2020-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On August 19th Johnson and Johnson announced that it had reached a final agreement to acquire Momenta, a company dedicated to the discovery and development of new immuno-mediated diseases, in an all-cash deal of about $6.5bn.
    the terms of the deal approved by the boards of directors of the two companies, Vigor Sub, a wholly owned subsidiary of Johnson and Johnson, will begin an offer.
    deal is expected to close in the second half of 2020.
    the acquisition will allow Janssen, a unit of Johnson and Johnson, to expand its leadership in immuno-mediated diseases.
    deal will include full global rights to nipodalimab (M281), a clinically proven anti-FCRn antibody that could be best-in-class.
    Jansen has the opportunity to advance the development of nipocalimab's adaptations to a variety of autoimmune diseases, including maternal fetal diseases, neurological diseases, rheumatism, dermatology and autoimmune blood disorders, all of which currently have a large number of unsolveed medical needs.
    recently qualified for the FDA's rare drug.
    addition to Momenta's employees and key asset nipodalimab, Jansen will acquire Momia's clinical and preclinical assets.
    autoimmune disease, which is partially or completely driven by autoantibodies, represents a new area in which Jansen can significantly improve the health of patients.
    in autoantibodies-driven diseases, the body's antibodies attack or destroy its own proteins, cells, and tissues, often with devastating consequences.
    autoantibodies-driven diseases include severe muscle weakness, hemolytic diseases in fetuses and newborns, warm antibody autoimmune hemolytic anemia, and other serious skin diseases, rheumatism, neuropathy, blood and kidney diseases.
    estimates that 2.5 percent of the world's population, about 195 million people, suffer from some form of autoantibodies-driven disease, many of which are rare.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.